Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
China (Chinese)
Profile Icon Profile Icon
登录/注册 UserName
产品

解决方案

发现&学习

资源&工具

Support

Search icon Search icon
Close Menu
      Alert Icon
      RB744 Biosimilar Anti-Human TNF
      RB744 Biosimilar Anti-Human TNF
      Multiparameter flow cytometric analysis of TNF (Infliximab Biosimilar) expression by stimulated Human peripheral blood lymphocytes. Human peripheral blood mononuclear cells (PBMC) were stimulated for 5 hours with Phorbol 12-Myristate 13-Acetate (Sigma P-8139; 50 ng/ml final concentration) and Ionomycin (Sigma I-0634; 1 μg/ml final concentration) in the presence of BD GolgiStop™ Protein Transport Inhibitor (containing Monensin) [Cat. No. 554724]. The cells were harvested, washed with BD Pharmingen™ Stain Buffer (FBS) [Cat. No. 554656] and fixed with BD Cytofix™ Fixation Buffer (Cat. No. 554655) followed by washing and permeabilization using BD Perm/Wash™ Buffer (Cat. No. 554723).        The fixed and permeabilized cells were then stained in BD Perm/Wash™ Buffer with either BD OptiBuild™ RB744 Human IgG1 (N297A), κ Isotype Control (Cat. No. 756837; Left Plot) or BD Horizon™ RB744 Biosimilar Anti-Human TNF antibody (Cat. No. 570957/571028; Right Plot). The bivariate pseudocolor density plot showing the correlated expression of TNF (or Ig Isotype control staining) versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry and data analysis were performed using a BD FACSymphony™ A5 SE Cell Analyzer and FlowJo™ Software.
      RB744 Biosimilar Anti-Human TNF
      Multiparameter flow cytometric analysis of TNF (Infliximab Biosimilar) expression by stimulated Human peripheral blood lymphocytes. Human peripheral blood mononuclear cells (PBMC) were stimulated for 5 hours with Phorbol 12-Myristate 13-Acetate (Sigma P-8139; 50 ng/ml final concentration) and Ionomycin (Sigma I-0634; 1 μg/ml final concentration) in the presence of BD GolgiStop™ Protein Transport Inhibitor (containing Monensin) [Cat. No. 554724]. The cells were harvested, washed with BD Pharmingen™ Stain Buffer (FBS) [Cat. No. 554656] and fixed with BD Cytofix™ Fixation Buffer (Cat. No. 554655) followed by washing and permeabilization using BD Perm/Wash™ Buffer (Cat. No. 554723).        The fixed and permeabilized cells were then stained in BD Perm/Wash™ Buffer with either BD OptiBuild™ RB744 Human IgG1 (N297A), κ Isotype Control (Cat. No. 756837; Left Plot) or BD Horizon™ RB744 Biosimilar Anti-Human TNF antibody (Cat. No. 570957/571028; Right Plot). The bivariate pseudocolor density plot showing the correlated expression of TNF (or Ig Isotype control staining) versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry and data analysis were performed using a BD FACSymphony™ A5 SE Cell Analyzer and FlowJo™ Software.
      商品详情
      Down Arrow Up Arrow


      BD Horizon™
      TNF; TNF-a; TNF-alpha; TNF-α; TNFA; tumor necrosis factor-alpha; Cachectin
      Human (QC Testing)
      Human IgG1, κ
      Human TNF
      Intracellular staining (flow cytometry) (Routinely Tested)
      5 µl/test
      7124
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      准备和存储

      The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions and unreacted dye was removed. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
      显示较多信息 blue down arrow 显示较少信息 blue up arrow

      推荐的实验流程

      BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

      显示较多信息 blue down arrow 显示较少信息 blue up arrow

      商品通知

      1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      3. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
      4. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      5. An isotype control should be used at the same concentration as the antibody of interest.
      6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      7. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
      8. For U.S. patents that may apply, see bd.com/patents.
      9. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
      10. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
      11. Tandem fluorochromes contain both an energy donor and an energy acceptor. Although every effort is made to minimize the lot-to-lot variation in the efficiency of the fluorochrome energy transfer, differences in the residual emission from the donor may be observed. Additionally, multi-laser cytometers may directly excite both the donor and acceptor fluorochromes. Therefore, we recommend for every tandem conjugate, a matched individual single-stain control be acquired for generating a compensation or spectral unmixing matrix.
      显示较多信息 blue down arrow 显示较少信息 blue up arrow
      571028 Rev. 1
      抗体详情
      Down Arrow Up Arrow
      Infliximab297.rMAb

      The Infliximab N297A Biosimilar.rMAb is a research grade recombinant Human IgG1, kappa monoclonal antibody that specifically recognizes Human Tumor Necrosis Factor (TNF) similarly to therapeutic Infliximab. Infliximab N297A Biosimilar.rMAb was engineered to code for a replacement of asparagine with alanine at position 297 (N297A) of the Human IgG1 heavy chain to reduce potential nonspecific staining caused by Fc receptor binding. Infliximab is a chimeric recombinant Human IgG1 Anti-Human TNF monoclonal antibody that is used to treat a wide variety of inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, Bechet's disease, psoriasis, septic shock, cachexia, and cancer. Therapeutic Infliximab specifically binds to soluble and transmembrane TNF and neutralizes its biological activity by blocking the binding to its cell surface receptors. It may also bind to transmembrane TNF on cells that produce it and mediate both antibody-dependent (ADCC) and complement-dependent (CDC) cytotoxicity. Infliximab does not bind to or inactivate lymphotoxin (Tumor necrosis factor-beta; TNF-ß). TNF, also known as TNF alpha (TNF-a) or Cachectin, is an ~26 kDa type II transmembrane protein that is encoded by TNF. TNF is a multifunctional cytokine that plays roles in inflammation, immune system development, innate and adaptive immune responses, apoptosis, lipid metabolism, and necrosis of some tumor cells. TNF is variably produced by a wide variety of activated leucocytes, epithelial cells, endothelial cells, and tumor cells. This mediator forms noncovalently bound homotrimers that are expressed on the cell surface. Membrane TNF is enzymatically cleaved from the cell surface by tumor necrosis factor alpha converting enzyme (TACE), also known as ADAM17 and CD156b, into a soluble biologically active trimer of the TNF extracellular domains. TNF mediates its biological activities through binding to cell surface TNF Receptor Type 1 (TNFR1, CD120a) and Type 2 (TNFR2, CD120b), which are widely expressed on normal hemopoietic and nonhemopoietic cells as well as tumor cells.

         The Infliximab N297A Biosimilar.rMAb is intended for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.

      571028 Rev. 1
      格式详情
      Down Arrow Up Arrow
      RB744
      The BD Horizon RealBlue™ 744 (RB744) Dye is part of the BD® family of blue dyes. It is a tandem fluorochrome with an excitation maximum (Ex Max) at 498-nm and an emission maximum (Em Max) at 746-nm as measured using an antibody-dye conjugate. Driven by BD® innovation, RB744 can be used on both spectral and conventional cytometers and is designed to be excited by the Blue laser (488-nm) with minimal excitation by the 561-nm Yellow-Green laser. For conventional instruments equipped with a Blue laser (488-nm), we recommend using an optical filter centered near 750-nm (e.g., a 750/60-nm bandpass filter).
      altImg
      RB744
      Blue 488 nm
      498 nm
      746 nm
      571028 Rev.1
      报价单和参考
      Down Arrow Up Arrow
      View product citations for antibody "571028" on CiteAb

      研发参考 (3)

      1. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.. Mol Immunol. 1993; 30(16):1443-53. (Biology: Blocking, ELISA, Radioimmunoassay). 查看参考
      2. Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.. Cytokine. 2018; 101:56-63. (Biology). 查看参考
      3. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.. Cytokine. 1995; 7(3):251-9. (Biology: Blocking, Cytotoxicity, Flow cytometry, Inhibition, Radioimmunoassay). 查看参考
      571028 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.